- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07671599
Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE) (PERUSE)
Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE): A Pilot Study
This prospective pilot study is exploratory in nature and is designed to evaluate the validity of continuous glucose monitor (CGM) use for perioperative glucose surveillance during scheduled Cesarean delivery for nondiabetic patients. Primary objective is characterization of perioperative glucose trends during elective Cesarean delivery in patients without diabetes and exploratory analyses will describe perioperative glucose patterns captured by CGM. Secondary objective is to examine rates of and associations with post-operative complications, including surgical site infections.
Studieoversikt
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Nicola F Tavella, MPH
- Telefonnummer: (212) 241-3888
- E-post: nicola.tavella@mssm.edu
Studer Kontakt Backup
- Navn: Kavya Shivashankar, MD
- Telefonnummer: (212) 241-5681
- E-post: kavya.shivashankar@mssm.edu
Studiesteder
-
-
New York
-
New York, New York, Forente stater, 10029
- Rekruttering
- Icahn School of Medicine at Mount Sinai
-
Ta kontakt med:
- Nicola F Tavella, MPH
- Telefonnummer: 2122413888
- E-post: nicola.tavella@mssm.edu
-
Hovedetterforsker:
- Angela Bianco
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
continuous glucose monitor (CGM) use for perioperative glucose surveillance during scheduled Cesarean delivery for nondiabetic patients
Beskrivelse
Inclusion Criteria:
- singleton pregnancy
- no prior diagnosis of diabetes (gestational included)
- scheduled term cesarean delivery in Mount Sinai Health System
- aged 18-50 years
Exclusion Criteria:
- preexisting diabetes mellitus
- diagnosis of gestational diabetes mellitus (GDM) in the current pregnancy, based on standard prenatal screening
- known endocrine disorder affecting glucose metabolism (such as Cushing syndrome, poorly controlled thyroid disorder, etc.)
- use of antenatal steroids within the two weeks prior to delivery
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
scheduled term c-section
Patients scheduled for term cesarean deliveries and who are screened eligible and consented will be administered a continuous glucose monitor prior to their c-section, and they will wear the device through their stay in the hospital. |
Continuous glucose monitor during perioperative Cesarean delivery |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
interstitial glucose from CGM device
Tidsramme: from pre-operative appointment through end of postpartum hospital stay, up to ten days
|
glucose of interstitial fluid as measured by CGM device on participant's arm |
from pre-operative appointment through end of postpartum hospital stay, up to ten days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of surgical site infection
Tidsramme: Post-op through end of postpartum hospital say, up to ten days.
|
Diagnosis of surgical site infection as a measure of post-operative complications |
Post-op through end of postpartum hospital say, up to ten days.
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Angela Bianco, MD, Faculty
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- STUDY-26-00229
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
All of the individual participant data collected during the trial, after deidentification.
IPD-delingstidsramme
Immediately following publication. No end date.
Tilgangskriterier for IPD-deling
Researchers who provide a methodologically sound proposal. To achieve aims in the approved proposal. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in the University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link tbd).
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .